APRE — Aprea Therapeutics Share News
0.000.00%
Last trade - 00:00- $6.52m
- -$33.99m
- $0.29m
Aprea Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Aprea Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aprea Therapeutics Reports Fourth Quarter Loss Per Share Of $0.36
Aprea Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Aprea Therapeutics Inc - Expects Cash And Cash Equivalents Of $50.0 Million To $55.0 Million (Unaudited) As Of Dec 31, 2021
Brief: Aprea Therapeutics Presents Primary Analysis From Phase 2 Trial Of Eprenetapopt + Azacitidine
Aprea rises as FDA removes clinical hold on cancer therapy study
Brief: Aprea Therapeutics Announces Removal Of FDA Clinical Hold On Eprenetapopt In Lymphoid Malignancies
Aprea Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aprea Therapeutics Posts Q3 Loss Per Share Of $0.45
Aprea Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Uber, Warner Music, Viridian Therapeutics
Aprea Therapeutics jumps on positive data from cancer drug candidate
U.S. RESEARCH ROUNDUP-Aprea Therapeutics, Duke Energy, Inovalon Holdings
Aprea Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Aprea Therapeutics Posts Q2 Loss Per Share Of $0.48
Brief: Aprea Therapeutics Announces Clinical Hold On Lymphoid Malignancy Program
Aprea Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Kaixin Auto, Dicerna Pharma, Yelp